Depletion of spinal 5-HT accelerates mechanosensory recovery in the deafferented rat spinal cord.
Dorsal root injuries (DRIs), resulting in the permanent disconnection of nerve roots from the spinal cord, lead to sensory impairments, including both the loss of sensation and the development of neuropathic pain in the affected limb. DRI results in axonal sprouting of intraspinal serotonergic fibers, but the functional consequences of this response to spinal deafferentation remains unclear. Here we aimed to clarify the role of descending serotonergic projections in both mechanosensation and pain following DRI. By ablating serotonergic input to the spinal cord via 5,7-dihydroxytryptamine (5,7-DHT) prior to DRI in rats, we found that serotonergic input to the dorsal horn normally inhibits the recovery of mechanosensation but has no effect on the development or resolution of cold pain. Endogenous brain-derived neurotrophic factor (BDNF) is upregulated by activated microglia, is required for sprouting of serotonergic axons and neuropeptide tyrosine (NPY)-positive interneurons, and suppresses mechanosensory recovery following DRI. Intriguingly, we found that the density of activated microglia, the amount of BDNF protein, and density of NPY-positive processes were all significantly reduced in 5,7-DHT-treated rats, suggesting that serotonergic input to the deafferented dorsal horn is required for all of these consequences of spinal deafferentation. These results indicate that BDNF-dependent serotonergic and/or increases in NPY-positive fiber density slows, and ultimately halts, mechanosensory recovery following DRI.
Cragg
J J
JJ
ICORD (International Collaboration on Repair Discoveries), Blusson Spinal Cord Centre, Vancouver, BC, Canada V5Z 1M9.
Scott
A L
AL
Ramer
M S
MS
D015116:5,7-Dihydroxytryptamine / Q000494:pharmacology; D000818:Animals; D001921:Brain / Q000378:metabolism; D019208:Brain-Derived Neurotrophic Factor / Q000378:metabolism; D015740:Calcitonin Gene-Related Peptide / Q000378:metabolism; D004195:Disease Models, Animal; D006930:Hyperalgesia / Q000503:physiopathology; D006987:Hypesthesia / Q000209:etiology / Q000503:physiopathology*; D037102:Lectins / Q000378:metabolism; D008297:Male; D017628:Microglia / Q000378:metabolism; D009478:Neuropeptide Y / Q000378:metabolism; D017288:Pain Threshold / Q000187:drug effects / Q000502:physiology; D010523:Peripheral Nervous System Diseases / Q000150:complications / Q000473:pathology; D010812:Physical Stimulation / Q000379:methods; D051381:Rats; D017207:Rats, Sprague-Dawley; D020127:Recovery of Function / Q000502:physiology*; D019051:Rhizotomy / Q000379:methods; D012701:Serotonin / Q000172:deficiency*; D018490:Serotonin Agents / Q000494:pharmacology; D050486:Serotonin Plasma Membrane Transport Proteins / Q000378:metabolism; D013116:Spinal Cord / Q000378:metabolism* / Q000473:pathology; D013126:Spinal Nerve Roots / Q000293:injuries / Q000378:metabolism / Q000503:physiopathology*; D014446:Tyrosine 3-Monooxygenase / Q000378:metabolism; D015854:Up-Regulation / Q000187:drug effects; D050598:Vesicular Glutamate Transport Protein 1 / Q000378:metabolism
D019208:Brain-Derived Neurotrophic Factor; D037102:Lectins; D009478:Neuropeptide Y; D018490:Serotonin Agents; D050486:Serotonin Plasma Membrane Transport Proteins; C493465:Slc17a7 protein, mouse; D050598:Vesicular Glutamate Transport Protein 1; D015116:5,7-Dihydroxytryptamine; D012701:Serotonin; D014446:Tyrosine 3-Monooxygenase; D015740:Calcitonin Gene-Related Peptide